GENYO (Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research)
- Dr. Sainz's research is focused on the identification of susceptibility variants for hematological malignancies (Multiple Myeloma, AML and ALL) as well as cancer-related infections such as Invasive Aspergillosis.
- His ongoing research projects evaluate the role of candidate genes using high throughput genotyping technologies.
- Likewise, gene expression patterns are correlated with genotyping data in order to determine the causative genetic variant(s).
- This strategy, which integrates different technologies, might allow the identification of biomarkers associated with or predicting disease onset and progression as well as provide key information for identifying the underlying genes.
- Dr. Juan Sainz is group leader at GENyO (Pfizer - University of Granada - Junta de Andaluca Centre for Genomics & Oncological Research) where he is developing his research in the field of Genomics and Oncology (www.genyo.es).
- He obtained his master degree in Biochemistry in 1998 from the University of Granada (Spain) and a PhD in 2002 working on endothelial and vascular dysfunction in hyperthyroidism-induced hypertension.
- Following the successful conclusin of this PhD, Dr. Sainz spent several years working at he Virgen de las Nieves University Hospital (Granada, Spain) and Centro de Investigaciones Biogicas (CSIC, Madrid, Spain) befote joining to the German Cancer Research Center (DKFZ; Heidelberg, Germany) as a senior scientist in 2009.
- Since then Dr. Sainz has worked on the identification of genetic variants (SNPs, indel, CNVs, etc...) associated with cancer (solid tumors and hematological malignancies), cancer progression and cancer-related complications such as graft versus host disease and opportunistic infections.
- In parallel, he aimed at analyzing the interaction of particular genetic variants and cancer risk (gender, obesity, type 2 diabetes, etc), life-style and environmental factors.
- Likewise, his research activity has been also focused on the characterization of genetic factors contributing to drug resistance.
- At GENYO, he is coordinating a team of 4 PhD students working in the Genomic Oncology department.
- 2011-Present. Group Leader. Biomarker development laboratory. Genomic Oncology department. GENyO (Pfizer - University of Granada - Junta de Andaluc Centre for Genomics & Oncological Research)
- 2009-2010 Senior Scientist. Influence of Obesity, Type-2 diabetes and estrogen metabolism-related single nucleotide polymorphisms on the risk of colorectal cancer. German Cancer Research Center (DKFZ, www.dkfz.de). Heidelberg. Germany.
- 2007-2008 Post-doctoral Fellowship. Identification of genetic biomarkers that determinate susceptibility to develop invasive pulmonary aspergillosis. Fungal research group. Hematology department. Virgen de las Nieves University Hospital , Granada. Spain.
- 2005-2006 Post-doctoral Visitor. Transcripcional activity of Runx3 and its isoforms: Regulation of immune system genes. Immunology department. Centro de investigaciones biolgicas (CIB, www.cib.csic.es/es). Consejo Superior de Investigaciones Cientficas (CSIC), Madrid, Spain
- 2004-2005 Post-doctoral Fellowship. Invasive aspergillosis in immunocompromized patients: GM antigen for earlier diagnosis. Hematology department. Virgen de las Nieves University Hospital , Granada, Spain
- 2003-2004 Fellowship in Rheumathology. Identification of clinically relevant biomarkers to predict Infliximab therapy outcome in rheumatoid arthritis patients. Virgen de las Nieves University Hospital , Granada. Spain.
- 2000-2003 PhD Fellowship. Research in Medical Physiology with emphasis on vascular reactivity and hypertension. Department of Human Physiology. Faculty of Medicine, University of Granada.
- 1999-2000 Biochemist. VIRCELL S.A. Department of ELISA Kits Production.